Key Takeaways
- • Real Diagnostics, a portfolio company of HCAP Partners, acquired SimplyTest, a maker of saliva-based oral health tests; terms were not disclosed.
- • The deal extends Real Diagnostics, a CLIA-certified laboratory in Reisterstown, Md., into oral health testing and gives it a route to serve dental practices.
- • SimplyTest's PERIO test, which uses a swish-and-spit saliva sample to detect gum disease pathogens, will continue without interruption, along with its provider support.
- • HCAP is a California lower-middle-market investor providing $5 million to $35 million of mezzanine debt and private equity to companies with $10 million to $100 million in revenue.
Summary
Real Diagnostics, a portfolio company of HCAP Partners, has acquired SimplyTest, a maker of saliva-based oral health tests, according to the publisher's summary of the transaction. Terms were not disclosed.
The acquisition takes Real Diagnostics, a CLIA-certified laboratory based in Reisterstown, Maryland, into oral health testing and allows it to serve dental practices. Real Diagnostics currently runs high-complexity PCR testing for urinary tract, sexually transmitted and respiratory infections, and provides toxicology services to hospitals, physicians and medical offices.
SimplyTest's flagship PERIO test uses a swish-and-spit saliva sample to detect key pathogens linked to gum disease. The test gives clinicians organism-level data to tailor therapy and track periodontal health. According to the announcement, the PERIO test and SimplyTest's provider support will continue without interruption following the deal.
HCAP, a California lower-middle-market investor, provides $5 million to $35 million of mezzanine debt and private equity to companies with $10 million to $100 million in revenue. The transaction illustrates the firm's strategy of building out portfolio companies through add-on acquisitions in specialized diagnostics.
The acquisition takes Real Diagnostics, a CLIA-certified laboratory based in Reisterstown, Maryland, into oral health testing and allows it to serve dental practices. Real Diagnostics currently runs high-complexity PCR testing for urinary tract, sexually transmitted and respiratory infections, and provides toxicology services to hospitals, physicians and medical offices.
SimplyTest's flagship PERIO test uses a swish-and-spit saliva sample to detect key pathogens linked to gum disease. The test gives clinicians organism-level data to tailor therapy and track periodontal health. According to the announcement, the PERIO test and SimplyTest's provider support will continue without interruption following the deal.
HCAP, a California lower-middle-market investor, provides $5 million to $35 million of mezzanine debt and private equity to companies with $10 million to $100 million in revenue. The transaction illustrates the firm's strategy of building out portfolio companies through add-on acquisitions in specialized diagnostics.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.